Clinical Trials Browser

Neoplasms × relatlimab × Clear all

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04095208 2025-10-02

CONGRATS

Phase 2 Active not recruiting

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT06237920 2025-09-03

TURANDORELA

Phase 2 Recruiting

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Phase 1 Completed

Neoplasms